IPHANasdaqBiological Products, (No Diagnostic Substances)US GAAP · USD

Innate Pharma SA

Innate Pharma SA is a French clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its portfolio includes antibody-based and antibody-drug conjugate programs aimed at solid tumors and hematologic cancers, with operations centered in Marseille and a U.S. office in Rockville, Maryland.

Ask about the company

Business

Share of revenue
Antibody-drug conjugates25 %

Targeted cancer therapeutics that combine an antibody with a cytotoxic payload.

Monoclonal antibodies25 %

Antibody programs designed to modulate immune pathways in cancer.

Clinical-stage oncology pipeline25 %

Drug candidates in early-to-mid clinical development for solid and blood cancers.

Collaboration and licensing revenue25 %

Income from partnered development and license agreements with biopharma companies.

Customers

Innate Pharma does not sell commercial medicines broadly; its counterparties are mainly pharmaceutical partners, research collaborators, and clinical development participants. Revenue is driven primarily by collaboration and licensing arrangements, including recognition of proceeds from partners such as AstraZeneca and Sanofi. Its internal customer base for development work also includes patients enrolled in clinical trials for specific cancer indications.

Biopharma collaboration partners

Sanofi, AstraZeneca, and similar partners that fund or co-develop pipeline assets and generate collaboration revenue.

Academic and research institutions

Institutions that collaborate on target discovery, translational research, and early oncology innovation.

Clinical trial sites and patients

Hospitals and enrolled patients participating in Phase 1 and other clinical studies for IPH4502, lacutamab, and monalizumab.

Strategy

The company’s strategy centers on advancing differentiated antibody-based cancer therapies toward clinical proof-of-concept and partnering programs where external capital and expertise can accelerate development. It emphasizes targets with high unmet medical need, including solid tumors and cutaneous/peripheral T-cell lymphomas, while using collaborations to broaden scientific reach and share development risk.

Advance IPH4502 through clinical developmentShort term

A differentiated ADC can create value if safety and activity translate into later-stage programs.

Progress lacutamab in T-cell lymphomasMedium term

Clinical validation in hematologic cancers can broaden the pipeline beyond solid tumors.

Maintain and expand partnershipsMedium term

Collaboration agreements can provide non-dilutive funding and external development capability.

Geography

Innate Pharma is headquartered in Marseille, France and maintains a U.S. office in Rockville, Maryland. Its development work is global, with clinical studies mentioned in France and the United States, and its public listings span Euronext Paris and Nasdaq in the U.S.

Risks

Innate Pharma faces the typical risks of clinical-stage biotechnology: pipeline failure, trial delays, and dependence on partner decisions for funded programs. Because its revenue is largely collaboration-based and its assets are still in development, outcomes depend heavily on clinical data, regulatory review, and the continuation of third-party agreements.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Clinical development failure1Regulatory and trial execution risk2Partner concentration3Foreign exchange volatility4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Clinical development failureImpact: CriticalLikelihood: High

    Pipeline value depends on IPH4502, lacutamab, and monalizumab showing safety and efficacy in trials.

    ExposureIPH4502LacutamabMonalizumab
  2. Regulatory and trial execution riskImpact: HighLikelihood: High

    Oncology programs require successful recruitment, endpoint achievement, and regulator acceptance.

    Exposure: Phase 1 and subsequent clinical studies

  3. Partner concentrationImpact: HighLikelihood: Medium

    Revenue and program continuity rely on collaborations with a small number of large biopharma partners.

    ExposureAstraZenecaSanofi
  4. Foreign exchange volatilityImpact: MediumLikelihood: High

    The company reports euro financials but holds U.S. dollar-denominated cash and collaboration liabilities.

    Exposure: EUR/USD balances

Ask Clarifo about Innate Pharma SA

Accounting

Judgemental items
Collaboration and license revenue recognition

Revenue is recognized as performance obligations are met, making timing and allocation judgments important.

Impact: Can cause quarter-to-quarter volatility in reported revenue

Fair value of financial assets

Short-term investments and non-current financial assets are marked using valuation techniques, including level 2 inputs.

Impact: Affects income and balance sheet carrying values

Deferred tax assets and tax losses

The company has substantial tax-loss carryforwards but does not recognize deferred tax assets where recovery is not probable.

Impact: Influences equity and future tax expense presentation

Lease accounting

Operating sites and office space create lease assets and liabilities under IFRS 16.

Impact: Affects reported debt-like obligations and depreciation/interest split

Similar listed companies

Publicly listed companies with a comparable business focus.

Incyte Corporation

INCY · Services-Commercial Physical & Biological Research

Intensity Therapeutics, Inc

INTS · Biological Products, (No Diagnostic Substances)

Inmune Bio, Inc.

INMB · Biological Products, (No Diagnostic Substances)

Immunome Inc.

IMNM · Pharmaceutical Preparations

IN8bio, Inc

INAB · Biological Products, (No Diagnostic Substances)

Actuate Therapeutics, Inc

ACTU · Pharmaceutical Preparations

Last updated: 28/09/2026

Innate Pharma SA (Nasdaq) – Biological Products, (No Diagnostic Subs | Financial Analysis – Clarifo